Targeting RAS: New Avenues and Challenges
RAS oncogenes were considered undruggable for decades. Yet, this situation changed considerably with the development of new drugs targeting different mutant isoforms culminating in the approval of the first RAS-targeting drug in 2021. Nevertheless, a better understanding of the basic principles of RAS signaling may guide the development of improved therapeutic options. The goal […]
